EC 1456

Drug Profile

EC 1456

Alternative Names: EC-1456; Folate-targeted tubulysin - Endocyte; Folate-tubulysin; Folic acid-tubulysin conjugate (EC1456) - Endocyte

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Endocyte
  • Class Antineoplastics; Biological toxins; Peptides; Small molecules
  • Mechanism of Action Folate receptor 1 antagonists; Mitosis inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-small cell lung cancer; Ovarian cancer; Solid tumours
  • Preclinical Breast cancer; Endometrial cancer

Most Recent Events

  • 02 Jun 2017 Updated adverse events and efficacy data from a phase I trial in Solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 24 Jan 2017 Phase-I clinical trials in Ovarian cancer (Late-stage disease) in USA (IV) (NCT03011320)
  • 03 Jan 2017 Endocyte plans an exploratory clinical trial for Ovarian cancer (Late-stage disease) in USA (NCT03011320)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top